Key result
Pre-procedural elevated serum visfatin was a significant positive predictor for recurrent atrial fibrillation after catheter ablation, demonstrating an area under the curve of 0.728.
Why the study?
Identifying patients at risk of recurrent AF could help develop preventive strategies and optimize patient selection for catheter ablation.
Do pre-procedural serum levels of visfatin, TNF-α, and other biomarkers predict recurrent atrial fibrillation after catheter ablation in patients with paroxysmal or persistent AF?
Cohort (n=117)
Do pre-procedural serum levels of visfatin, TNF-α, and other biomarkers predict recurrent atrial fibrillation after catheter ablation in patients with paroxysmal or persistent AF?
Pre-procedural elevated serum levels of visfatin, TNF-α, and adiponectin may serve as useful biomarkers to predict the risk of recurrent atrial fibrillation following catheter ablation.
Answers are grounded in this paper and cite their sources.
May aid recurrence risk stratification before AF ablation; hypothesis-generating and needs prospective validation before clinical adoption.
BACKGROUND: Many patients would require repeated ablation procedures owing to recurrent atrial fibrillation with its associated symptoms. Identifying those who are at risk of recurrent AF could assist us to develop preventive strategies and to properly select those who will benefit more from catheter ablation. Our aim is to study the role of preprocedural serum level of certain biomarkers in the prediction of AF recurrence after catheter ablation. RESULTS: The present study included 117 patients: 26 patients with persistent and 91 patients with paroxysmal AF. Blood samples for estimation of serum levels of studied cytokines were obtained prior to the procedure. Pulmonary vein isolation was performed in all patients through point-by point radiofrequency ablation guided by 3D electroanatomical mapping system. Patients were followed for 12 months for AF recurrence. Forty-one (35%) patients developed AF recurrence. Those patients were significantly older, had significantly higher BMI, lower ejection fraction, and wider maximal left atrial diameter (LAD). Serum hs-CRP, IL-6, TNF-α, visfatin, and adiponectin levels were significantly higher compared to those who did not develop AF recurrence. Correlation analysis showed positive correlations between the incidence of RAF and patients' age, BMI, and maximum LAD and elevated cytokine levels and maximal LAD showed significant correlations with the type of AF and elevated serum TNF-α, visfatin, and adiponectin. Statistical analyses defined elevated serum levels of TNF-α, visfatin, and adiponectin as positive predictors for RAF, and automatic linear modeling analysis showed that elevated serum visfatin, TNF-α, and adiponectin can predict RAF by accuracy rates of 50%, 34%, and 16%, respectively. CONCLUSIONS: RAF is most probably an outcome of the interplay between patients' clinical data, obesity, and inflammation. Pre-procedural estimation of serum levels of visfatin and TNF-α might determine patients with probability for RAF.
No takes yet. Share an insight, caveat, or question.
Al-Kassas et al. (2023) conducted a cohort in Symptomatic paroxysmal or persistent atrial fibrillation (n=117). Pre-procedural elevated serum visfatin vs. Lower serum visfatin levels was evaluated on Incidence of recurrent atrial fibrillation (RAF) at 12 months (AUC 0.728, 95% CI 0.624-0.832, p=<0.0001). Pre-procedural elevated serum visfatin was a significant positive predictor for recurrent atrial fibrillation after catheter ablation, demonstrating an area under the curve of 0.728.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: